Concepedia

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

Ignace Vergote, N. Finkler, J. Del Campo, Alfredo Löhr, James E. Hunter, Daniela Matei, J. J. Kavanagh, Jan B. Vermorken, Marsha Jones, Gina Brown,

European Journal of Cancer · 2009 · 102 citations · 16 references

DOI

Concepts

References

16

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +12

Cancer Statistics, 2006

Ahmedin Jemal, Rebecca L. Siegel, Elizabeth M. Ward et al. · CA A Cancer Journal for Clinicians · 2006 · 5.3K citations · Full text

, , +16

Cancer Statistics, 2001

Robert T. Greenlee, M. B. Hill-Harmon, Thomas S. Murray et al. · CA A Cancer Journal for Clinicians · 2001 · 3.3K citations · Full text

, , +16

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

Alan N. Gordon, John Fleagle, David Guthrie et al. · Journal of Clinical Oncology · 2001 · 1.2K citations

, , +16

Annual Report to the Nation on the Status of Cancer, 1975–2002, Featuring Population-Based Trends in Cancer Treatment

Brenda K. Edwards, Martin L. Brown, Phyllis A. Wingo et al. · JNCI Journal of the National Cancer Institute · 2005 · 955 citations · Full text

, , +17